This phase II trial will evaluate, in first line advanced or metastatic gastric cancer, the efficacy and tolerance of another oxaliplatin, 5FU bolus combination already tested in advanced colorectal cancer

Inclusion Criteria:

• Histologically proven gastric or gastroesophagic junction adenocarcinoma
• Measurable disease at least in a unidimensional manner. If a unique metastasis constitutes the only disease symptom, histological confirmation will be required
• Metastatic or locally non-surgical primary gastric cancer
• Recurrent gastric cancer after local and/or systemic treatment with a post-surgical period of at least 4 weeks, a post-adjuvant chemotherapy period or a neo-adjuvant chemo-radiotherapy of at least 6 months
• Serum bilirubin< 2 mg/dl
• Serum creatinine < or =to 2 times normal superior limit
• Absolute neutrophil count > or =to 2000/dl
• Platelet count > or =to 100000/dl
• Hemoglobin > or =to 10 g/dl
• AST/ALT < or =to 2.5 times normal superior institutional limit
• Alkaline phosphatase < or =to 5 times the normal superior institutional limit
• Age > 18 years
• Performance Status ECOG 0-2
• Written informed consent signed and dated

Exclusion Criteria:

• Symptomatic sensory peripheral neuropathy
• Uncontrolled concomitant disease.(e.g. severe diabetes mellitus, arterial hypertension)
• Any other malignancy diagnosed within 5 years previous to the gastric cancer, with the exception of " in situ " cervix carcinoma or non-melanoma skin cancer
• Concomitant anti-tumoral treatment
• Cerebral metastases
• Unstable heart disease, even though under treatment
• Myocardial infarction within the last 6 months
• Pregnancy or nursing (or women in reproductive life without adequate contraception)
• Significant neurological or psychiatric disorders